Tech Company Financing Transactions
MyoKardia Funding Round
MyoKardia closed a $38 million investment round on 9/21/2012. Investors included Third Rock Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/21/2012
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Undisclosed
Investors
Third Rock Ventures (Lead Investor) (Charles Homcy)
Proceeds Purpose
The initial plan is to go after hypertrophic cardiomyopathy and dilated cardiomyopathy, with a handful of drugs matched up to specifically treat a handful of different genetic forms of the disease.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1000 Sierra Point Pkwy.
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company's first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tassos Gianakakos
Chief Financial Officer
Taylor Harris
Chief Medical Officer
Marc Semigran
Chief Scientific Officer
Robert McDowell
VP - Bus. Development
Jake Bauer
VP - Human Resources
Ingrid Boyes
Browse more venture capital transactions:
Prev: 9/21/2012: e2e Materials venture capital transaction
Next: 9/21/2012: ContinuumRx venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs